Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myeloma.

Raphael TeipelSusanne RieprechtKarolin Trautmann-GrillChristoph RölligChristina KlötzerKristin ZimmerGrit RathajEnrica BachMandy BrücknerSimone HeynSong-Yau WangMadlen JentzschSebastian SchwindTheresa KretschmannKatharina Egger-HeidrichYvonne RemaneGeorg-Nikolaus FrankeMalte von BoninMartin BornhäuserUwe PlatzbeckerKristina HöligMaximilian MerzVladan Vucinic

Published in: Transfusion (2023)

Stem cell collection in patients undergoing anti-CD38-based induction therapy is feasible with either CM or SSM, although SSM more frequently requires plerixafor.

Keyphrases

stem cells
newly diagnosed
patients undergoing
multiple myeloma
cell therapy
bone marrow
single cell
squamous cell carcinoma
nk cells
replacement therapy
smoking cessation